Table 1.

Effect of PAF Treatment on the Ability of BMSC to Support BFU-E Colony Formation From Autologous CD34+ Cells

Culture ConditionsExp 1Exp 2Exp 3Exp 4
Control 29 ± 2* 45 ± 8 34 ± 8 24 ± 3 
PAF 55 ± 5 72 ± 7 50 ± 7 39 ± 4 
WEB2170 31 ± 3 49 ± 5 37 ± 7 24 ± 1 
PAF + WEB2170 28 ± 3 43 ± 6 48 ± 3 30 ± 3 
Control + anti-PRL 25 ± 4 39 ± 5 31 ± 7 20 ± 1 
PAF + anti-PRL 33 ± 3 56 ± 4 46 ± 3 27 ± 6 
WEB2170 + anti-PRL 26 ± 2 40 ± 5 36 ± 11 24 ± 5 
PAF + WEB2170 + anti-PRL 27 ± 5 46 ± 7 35 ± 10 23 ± 4 
Culture ConditionsExp 1Exp 2Exp 3Exp 4
Control 29 ± 2* 45 ± 8 34 ± 8 24 ± 3 
PAF 55 ± 5 72 ± 7 50 ± 7 39 ± 4 
WEB2170 31 ± 3 49 ± 5 37 ± 7 24 ± 1 
PAF + WEB2170 28 ± 3 43 ± 6 48 ± 3 30 ± 3 
Control + anti-PRL 25 ± 4 39 ± 5 31 ± 7 20 ± 1 
PAF + anti-PRL 33 ± 3 56 ± 4 46 ± 3 27 ± 6 
WEB2170 + anti-PRL 26 ± 2 40 ± 5 36 ± 11 24 ± 5 
PAF + WEB2170 + anti-PRL 27 ± 5 46 ± 7 35 ± 10 23 ± 4 

Abbreviations: anti-PRL, rabbit antiserum to human prolactin; WEB2170, PAF receptor antagonist.

*

Data represent the mean ± SD number of BFU-E colonies per well in triplicate cultures each seeded with 5 × 102 cells. Cultures were performed in the presence of IL-3, GM-CSF, and Epo. No nonspecific inhibition was observed when using a nonimmune rabbit antiserum (not shown).